Arthritis gene therapy trials reach phase II

Editorial

Christopher Evans. J Rheumatol. 2010 Apr.

. 2010 Apr;37(4):683-5.

doi: 10.3899/jrheum.100055.

No abstract available

Comment on

Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study.
Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, Hobbs KF, Greenwald M, Hou A, Bookbinder SA, Graham GE, Wiesenhutter CW, Willis L, Ruderman EM, Forstot JZ, Maricic MJ, Dao KH, Pritchard CH, Fiske DN, Burch FX, Prupas HM, Anklesaria P, Heald AE. Mease PJ, et al. J Rheumatol. 2010 Apr;37(4):692-703. doi: 10.3899/jrheum.090817. Epub 2009 Dec 23. J Rheumatol. 2010. PMID: 20032102 Clinical Trial.

1. Bandara G, Robbins PD, Georgescu HI, Mueller GM, Glorioso JC, Evans CH. Gene transfer to synoviocytes: prospects for gene treatment of arthritis. DNA Cell Biol 1992;11:227–31. - PubMed
1. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy for arthritis: what next? Arthritis Rheum 2006;54:1714–29. - PubMed
1. Evans CH, Ghivizzani SC, Robbins PD. Gene therapy of the rheumatic diseases: 1998 to 2008. Arthritis Res Ther 2009;11:209. - PMC - PubMed
1. Evans CH. Gene therapy at an inflection point. Future Rheumatol 2008;3:207–10.
1. Evans CH, Robbins PD, Ghivizzani SC, Wasko MC, Tomaino MM, Kang R, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. Proc Natl Acad Sci USA 2005;102:8698–703. - PMC - PubMed